NDAORALTABLET, EXTENDED RELEASE
Approved
Oct 2017
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
20
Data completeness
6/8 — Strong
LYRICA CR (pregabalin) by Viatris (2) is 2 ‑delta site (an auxiliary subunit of voltage‑gated calcium channels) in central nervous system tissues. First approved in 2017.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LYRICA CR (pregabalin) is an extended-release oral tablet that binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system. It reduces calcium-dependent release of pain neurotransmitters and modulates descending pain pathways to treat neuropathic pain and other chronic pain conditions. The mechanism does not involve direct GABA receptor binding, sodium channel blockade, or opioid receptor activity.
$0.402MPart D
LOE ApproachingDeclining
10mo to LOEWith LOE imminent (0.9 years remaining), the brand team is in defensive mode managing market erosion and preparing for generic competition.
Mechanism of Action
2 ‑delta site (an auxiliary subunit of voltage‑gated calcium channels) in central nervous system tissues. Although the mechanism of action of pregabalin has not been fully elucidated, results with genetically modified mice and with compounds structurally related to pregabalin (such as gabapentin)…
Indications
Worked on LYRICA CR at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.